In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financing Quarterly Statistics, Q3 2021

A Look At Financing Activity Across The Biopharma, Medical Device And In Vitro Diagnostics Industries, July-September 2021

Executive Summary

For the third quarter of 2021, biopharmas brought in an aggregate $17.4bn in financing and device company fundraising totaled $3.4bn; while in vitro diagnostic firms and research tools players raised $2.5bn.

You may also be interested in...



Deals In Depth: October 2021

Six $1bn+ alliances were penned in October. Topping the list was a potential $3.6bn deal between Poseida Therapeutics and Takeda to utilize Poseida's genetic engineering platforms for the research and development of up to eight gene therapies. The collaboration will focus on non-viral in vivo gene therapy programs, including Poseida's preclinical hemophilia A program P-FVIII-101. Poseida will lead research activities up to candidate selection, after which Takeda will assume responsibility for further exclusive global development and commercialization.

Dealmaking Quarterly Statistics, Q3 2021

In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.

Dealmaking Quarterly Statistics, Q3 2021

During Q3, biopharma merger and acquisition value reached $48.6bn and drew in $43bn in potential deal value (PDV) from alliances. Device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.

Topics

UsernamePublicRestriction

Register

IV124918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel